var data={"title":"Temozolomide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Temozolomide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7017?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=temozolomide-drug-information\" class=\"drug drug_general\">see &quot;Temozolomide: Drug information&quot;</a> and <a href=\"topic.htm?path=temozolomide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Temozolomide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225270\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Temodar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225271\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACH-Temozolomide;</li>\n      <li>ACT Temozolomide;</li>\n      <li>Temodal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050179\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Alkylating Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050171\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=temozolomide-drug-information\" class=\"drug drug_general\">see &quot;Temozolomide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Temozolomide is associated with a moderate emetic potential (Roila 2010 ); antiemetics are recommended to prevent nausea and vomiting. Prior to dosing, ANC should be &ge;1,500/mm<sup>3</sup> and platelets &ge;100,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dose, frequency, number of doses, and start date may vary by protocol and treatment phase. Refer to individual protocols.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neuroblastoma, relapsed or refractory:</b> Infants, Children, and Adolescents: Oral: 100 mg/m<sup>2</sup>/dose once daily for 5 days, repeat cycle every 21 days for up to 6 cycles; use in combination with irinotecan; administer 1 hour prior to irinotecan (Bagatell 2011). <b>Note:</b> Temozolomide doses were rounded to the nearest capsule size.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ewing&rsquo;s sarcoma, recurrent or progressive:</b> Children &ge;2 years and Adolescents: Oral: 100 mg/m<sup>2</sup>/dose once daily for 5 days, repeat cycle every 21 days (in combination with irinotecan; administer 1 hour prior to irinotecan) (Casey 2009); dosing based on a retrospective review</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Solid tumors, relapsed or refractory</b> [including but not limited to brain tumor (astrocytomas, gliomas, medulloblastoma), neuroblastoma, and sarcomas]: Infants, Children, and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling: Children &ge;3 years and Adolescents: 160 to 200 mg/m<sup>2</sup>/dose once daily for 5 days every 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternative dosing: 200 to 215 mg/m<sup>2</sup>/dose days 1 to 5 every 21 to 28 days; dose was decreased to 180 mg/m<sup>2</sup>/dose for patients who received prior craniospinal irradiation or relapsed after bone marrow transplant (De Sio 2006; Nicholson 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anaplastic  astrocytoma (refractory):</b> Oral, IV: Initial dose: 150 mg/m<sup>2</sup> once daily for 5 consecutive days of a 28-day treatment cycle. If ANC &ge;1,500/mm<sup>3</sup> and platelets &ge;100,000/mm<sup>3</sup>, on day 1 of subsequent cycles, may increase to 200 mg/m<sup>2</sup> once daily for 5 consecutive days of a 28-day treatment cycle. May continue until disease progression.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage modification for toxicity:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ANC &lt;1,000/mm<sup>3</sup> or platelets &lt;50,000/mm<sup>3</sup> on day 22 or day 29 (day 1 of next cycle): Postpone therapy until ANC &gt;1,500/mm<sup>3</sup> and platelets &gt;100,000/mm<sup>3</sup>; reduce dose by 50 mg/m<sup>2</sup>/day (but not below 100 mg/m<sup>2</sup>) for subsequent cycle</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ANC 1000 to 1500/mm<sup>3</sup> or platelets 50,000-100,000/mm<sup>3</sup> on day 22 or day 29 (day 1 of next cycle): Postpone therapy until ANC &gt;1500/mm<sup>3</sup> and platelets &gt;100,000/mm<sup>3</sup>; maintain initial dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Glioblastoma multiforme (newly diagnosed, high-grade glioma):</b> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Concomitant phase:</i></b> 75 mg/m<sup>2</sup>/day for 42 days with focal radiotherapy (60 Gy administered in 30 fractions). <b>Note:</b> PCP prophylaxis is required during concomitant phase and should continue in patients who develop lymphocytopenia until lymphocyte recovery to &le;grade 1. Obtain weekly CBC.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continue at 75 mg/m<sup>2</sup>/day throughout the 42-day concomitant phase (up to 49 days) as long as ANC &ge;1,500/mm<sup>3</sup>, platelet count &ge;100,000/mm<sup>3</sup>, and nonhematologic toxicity &le;grade 1 (excludes alopecia, nausea/vomiting)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Dosage modification for toxicity:</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">ANC &ge;500/mm<sup>3</sup> but &lt;1,500/mm<sup>3</sup> <b>or</b> platelet count &ge;10,000/mm<sup>3</sup> but &lt;100,000/mm<sup>3</sup> <b>or</b> grade 2 nonhematologic toxicity (excludes alopecia, nausea/vomiting): Interrupt therapy</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">ANC &lt;500/mm<sup>3</sup> <b>or</b> platelet count &lt;10,000/mm<sup>3</sup> <b>or</b> grade 3/4 nonhematologic toxicity (excludes alopecia, nausea/vomiting): Discontinue therapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Maintenance phase (consists of 6 treatment cycles):</i></b> Begin 4 weeks after concomitant phase completion. <b>Note:</b> Each subsequent cycle is 28 days (consisting of 5 days of drug treatment followed by 23 days without treatment). Draw CBC within 48 hours of day 22; hold next cycle and do weekly CBC until ANC &gt;1500/mm<sup>3</sup> and platelet count &gt;100,000/mm<sup>3</sup>; dosing modification should be based on lowest blood counts and worst nonhematologic toxicity during the previous cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Cycle 1: 150 mg/m<sup>2</sup> once daily for 5 days of a 28-day treatment cycle</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Cycles 2 to 6: May increase to 200 mg/m<sup>2</sup> once daily for 5 days; repeat every 28 days (if ANC &ge;1,500/mm<sup>3</sup>, platelets &ge;100,000/mm<sup>3</sup> and nonhematologic toxicities for cycle 1 are &le;grade 2 [excludes alopecia, nausea/vomiting]); <b>Note:</b> If dose was not escalated at the onset of cycle 2, do not increase for cycles 3 to 6).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dosage modification (during maintenance phase) for toxicity:</i></p>\n    <p style=\"text-indent:-4em;margin-left:12em;\">ANC &lt;1,000/mm<sup>3</sup>, platelet count &lt;50,000/mm<sup>3</sup>, or grade 3 nonhematologic toxicity (excludes alopecia, nausea/vomiting) during previous cycle: Decrease dose by 1 dose level (by 50 mg/m<sup>2</sup>/day for 5 days), unless dose has already been lowered to 100 mg/m<sup>2</sup>/day, then discontinue therapy.</p>\n    <p style=\"text-indent:-4em;margin-left:12em;\">If dose reduction &lt;100 mg/m<sup>2</sup>/day is required or grade 4 nonhematologic toxicity (excludes alopecia, nausea/vomiting), or if the same grade 3 nonhematologic toxicity occurs after dose reduction: Discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment:</b> Adults: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;36 mL/minute/m<sup>2</sup>: No effect on temozolomide clearance was demonstrated</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe renal impairment (CrCl &lt;36 mL/minute/m<sup>2</sup>): Use with caution; no dosage  adjustments provided in manufacturers labeling</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis patients: Use has not been studied</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment:</b> Adults: Severe hepatic impairment: Use with caution; no dosage adjustments provided in manufacturer&rsquo;s labeling</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225246\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Temodar: 5 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Temodar: 20 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Temodar: 140 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Temodar: 180 mg, 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Temodar: 100 mg (1 ea) [pyrogen free; contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225232\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050182\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Temozolomide is associated with a moderate emetic potential (Dupuis 2011; Roila 2010); antiemetics are recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Oral: Swallow capsule intact with a glass of water; do not chew; if patient is unable to swallow capsule, open capsule and dissolve in apple juice or applesauce taking precautions to avoid exposure to the cytotoxic agent; administer on an empty stomach or at bedtime to reduce the incidence of nausea and vomiting; absorption is affected by food; may administer with food as long as food intake and administration are performed at the same time each day to ensure consistent bioavailability. Do not repeat if vomiting occurs after dose is administered; wait until the next scheduled dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Parenteral: IV:  Infuse over 90 minutes. Infusion must be completed within 14 hours of reconstitution. Flush line before and after administration; may be administered through the same IV line as NS. Do not administer other medications through the same IV line. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132830\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV preparation, double gloves, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) are recommended. Double gloving, a gown, and (if dosage form allows) CSTDs are required during IV administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225265\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule: Store at room temperature of 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store intact vials refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Reconstituted vials may be stored for up to 14 hours at room temperature of 25&deg;C (77&deg;F); infusion must be completed within 14 hours of reconstitution. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050181\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of refractory anaplastic astrocytoma with progression after initial therapy with a nitrosourea and procarbazine (FDA approved in adults); treatment of newly-diagnosed glioblastoma multiforme (initially in combination with radiotherapy, then as maintenance treatment) (FDA approved in adults)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Active against recurrent glioblastoma multiforme, low-grade astrocytoma, low-grade oligodendroglioma, metastatic CNS lesions, refractory primary CNS lymphoma, anaplastic oligodendroglioma, primitive neuroectodermal tumors (PNET), including medulloblastoma, pediatric neuroblastoma, advanced or metastatic melanoma, cutaneous T-cell lymphomas [mycosis fungoides (MF) and Sezary Syndrome (SS)], carcinoid tumors, advanced neuroendocrine tumors (carcinoid or islet cell), Ewing&rsquo;s sarcoma (recurrent or progressive), soft tissue sarcomas (extremity/retroperitoneal/intra-abdominal or hemangiopericytoma/solitary fibrous tumor)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3402099\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Temodar may be confused with Tambocor</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Temozolomide may be confused with temsirolimus</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225305\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">With CNS malignancies, it may be difficult to distinguish between CNS adverse events caused by temozolomide versus the effects of progressive disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal gait, amnesia, anxiety, ataxia, confusion, depression, dizziness, drowsiness, fatigue, headache, hemiparesis, insomnia, memory impairment, paresis, paresthesia, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, erythema, pruritus, skin rash, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypercorticoidism, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dysgeusia, dysphagia, nausea (less common in grades 3/4), stomatitis, vomiting (less common in grades 3/4)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Mastalgia (less common in females), urinary frequency, urinary incontinence, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (less common in grades 3/4), leukopenia (more common in grades 3/4), lymphocytopenia (more common in grades 3/4), neutropenia (more common in grades 3/4), thrombocytopenia (more common in grades 3/4)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, diplopia, visual disturbance (visual deficit/vision changes)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, dyspnea, pharyngitis, upper respiratory tract infection, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, radiation injury (less common in maintenance phase after radiotherapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare by important or life-threatening: Agitation, anaphylaxis, apathy, aplastic anemia, bacterial infection, cholestasis, cytomegalovirus disease (primary and reactivation), diabetes insipidus, emotional lability, erythema multiforme, febrile neutropenia, flu-like symptoms, fungal infection, hallucination, hematoma, hemorrhage, hepatitis, hepatitis B (reactivation), hepatotoxicity, herpes simplex infection, herpes zoster, hyperbilirubinemia, hyperglycemia, hypersensitivity pneumonitis, hypokalemia, increased serum alkaline phosphatase, increased serum transaminases, injection site reaction (erythema, irritation, pain, pruritus, swelling, warmth), interstitial pneumonitis, metastases (including myeloid leukemia), myelodysplastic syndrome, neuropathy, opportunistic infection (including pneumocystosis), oral candidiasis, pancytopenia (may be prolonged), peripheral neuropathy, petechia, pneumonitis, pulmonary fibrosis, Stevens-Johnson syndrome, toxic epidermal necrolysis, weight loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225252\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, allergic reaction, anaphylaxis, urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis) to temozolomide or any component of the formulation; hypersensitivity to dacarbazine (both drugs are metabolized to MTIC)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in U.S. labeling): Not recommended in patients with severe myelosuppression</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225236\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Myelosuppression may occur; may require treatment interruption, dose reduction and/or discontinuation; monitor blood counts. An increased incidence has been reported in geriatric and female patients. Prolonged pancytopenia resulting in aplastic anemia has been reported (may be fatal); concurrent use of temozolomide with medications associated with aplastic anemia (eg, carbamazepine, co-trimoxazole, phenytoin) may obscure assessment for development of aplastic anemia. ANC should be &ge;1,500/mm<sup>3</sup> and platelets &ge;100,000/mm<sup>3</sup> prior to treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Temozolomide is associated with a moderate emetic potential (Dupuis 2011; Hesketh 2017; Roila 2016); antiemetics are recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Hepatotoxicity has been reported; may be severe or fatal. Monitor liver function tests at baseline, halfway through the first cycle, prior to each subsequent cycle, and at ~2 to 4 weeks after the last dose. Postmarketing reports of hepatotoxicity have included liver function abnormalities, hepatitis, hepatic failure, cholestasis, hepatitis cholestasis, jaundice, cholelithiasis, hepatic steatosis, hepatic necrosis, hepatic lesion, and hepatic encephalopathy (Sarganas 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pneumonia: <i>Pneumocystis jirovecii</i> pneumonia (PCP) may occur; risk is increased in those receiving steroids or longer dosing regimens. Monitor all patients for development of PCP (particularly if also receiving corticosteroids). PCP prophylaxis is required in patients receiving radiotherapy in combination with the 42-day temozolomide regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancies: Rare cases of myelodysplastic syndrome and secondary malignancies, including myeloid leukemia, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment; has not been studied in dialysis patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion time: Bioequivalence has only been established when IV temozolomide is administered over 90 minutes; shorter or longer infusion times may result in suboptimal dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Temozolomide resistance: Increased MGMT (O-6-methylguanine-DNA methyltransferase) activity/levels within tumor tissue is associated with temozolomide resistance. Glioblastoma patients with decreased levels (due to methylated MGMT promoter) may be more likely to benefit from the combination of radiation therapy and temozolomide (Hegi 2008; Stupp 2009). Determination of MGMT status may be predictive for response to alkylating agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300110\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6223210\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12823&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May enhance the adverse/toxic effect of Temozolomide. Valproate Products may increase the serum concentration of Temozolomide.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225266\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food reduces rate and extent of absorption. Management: Administer consistently either with food or without food (was administered in studies under fasting and nonfasting conditions).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225242\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225255\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. May cause fetal harm when administered to pregnant women. Male and female patients should avoid pregnancy while receiving temozolomide.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050178\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with ANC (absolute neutrophil count) and platelet count; monitor for CNS effects, gastrointestinal disturbance, myelosuppression, opportunistic infection, vision disturbance, and cough on a regular basis; dosage adjustments may be necessary for toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225235\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Temozolomide is a prodrug which is rapidly and nonenzymatically converted to the active alkylating metabolite MTIC [(methyl-triazene-1-yl)-imidazole-4-carboxamide]; this conversion is spontaneous, nonenzymatic, and occurs under physiologic conditions in all tissues to which it distributes. The cytotoxic effects of MTIC are manifested through alkylation (methylation) of DNA at the O<sup>6</sup>, N<sup>7</sup> guanine positions which lead to DNA double strand breaks and apoptosis. Non-cell cycle specific.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225251\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid and complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Parent drug: 0.4 L/kg; penetrates blood-brain barrier; CSF levels are ~35% to 39% of plasma levels (Yung 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 15% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Prodrug, hydrolyzed to the active form, MTIC; MTIC is eventually eliminated as CO<sub>2</sub> and 5-aminoimidazole-4-carboxamide (AIC), a natural constituent in urine; CYP isoenzymes play only a minor role in metabolism (of temozolomide and MTIC)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 100% (on a mg-per-mg basis, IV temozolomide, infused over 90 minutes, is bioequivalent to an oral dose) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Mean: Parent drug: Children: 1.7 hours; Adults: 1.6-1.8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: Empty stomach: 1 hour; with food (high-fat meal): 2.25 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~38%; parent drug 6%); feces &lt;1%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance: 5.5 L/hour/m<sup>2</sup>; women have a &sim;5% lower clearance than men (adjusted for body surface area); children 3-17 years have similar temozolomide clearance as adults </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050186\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">To minimize the risk of a wrong dose error, each strength of temozolomide must be packaged and dispensed in a separate vial or in its original glass bottle. Label each container with the appropriate number of capsules to be taken each day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4152326\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;\">A 10 mg/mL temozolomide oral suspension may be compounded in a vertical flow hood. Mix the contents of ten 100 mg capsules and 500 mg of povidone K-30 powder in a glass mortar; add 25 mg anhydrous citric acid dissolved in 1.5 mL purified water and mix to a uniform paste; mix while adding 50 mL Ora-Plus in incremental proportions. Transfer to an amber plastic bottle, rinse mortar 4 times with small portions of either Ora-Sweet or Ora-Sweet SF, and add quantity of Ora-Sweet or Ora-Sweet SF sufficient to make 100 mL. Store in plastic amber prescription bottles; label &quot;shake well&quot; and &quot;refrigerate&quot;; include the beyond-use date. Stable for 7 days at room temperature or 60 days refrigerated (preferred).</p>\n    <div class=\"reference\">Trissel LA, Yanping Z, and Koontz SE, &quot;Temozolomide Stability in Extemporaneously Compounded Oral Suspension,&quot; <i>Int J Pharm Compound</i>, 2006, 10(5):396-9.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225254\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Temodar Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (5): $136.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (5): $546.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (5): $2,733.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">140 mg (5): $3,827.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (5): $4,920.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $1,366.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Temozolomide Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (5): $71.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (5): $287.81</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (5): $1,438.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">140 mg (5): $2,014.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (5): $2,589.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (5): $3,598.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Temodar Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $1,203.73</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225257\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Advecit (TR);</li>\n      <li>Astrodal (SG);</li>\n      <li>Astromide (AU, NZ);</li>\n      <li>Blastomat (HR, LV, NL, RO);</li>\n      <li>Dralitem (EC, PY);</li>\n      <li>Hliozomid (UA);</li>\n      <li>Niman (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Rubrum ASF (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Temo (IL);</li>\n      <li>Temobela (VN);</li>\n      <li>Temodal (AE, AR, AT, AU, BE, BG, BH, BO, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IQ, IR, IT, JO, JP, KR, KW, LB, LT, LU, LY, MT, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PL, PR, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, SY, TH, TR, TW, UA, UY, VE, VN, YE);</li>\n      <li>Temodal IV (SG);</li>\n      <li>Temolde (KR);</li>\n      <li>Temomedac (IE, IS);</li>\n      <li>Temomedak (UA);</li>\n      <li>Temonix (BD);</li>\n      <li>Temotec (LK);</li>\n      <li>Temovex (PH);</li>\n      <li>Temozam (PH);</li>\n      <li>Temozol (LK, PH);</li>\n      <li>Viztemo (UA);</li>\n      <li>Zolomide (BD);</li>\n      <li>Zolotem-250 (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, and Paquet A Jr, &quot;Polysorbate 80 and E-Ferol Toxicity,&quot; <i>Pediatrics</i>, 1986, 77(4):593-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bagatell R, London WB, Wagner LM, &quot;Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study,&quot; <i>J Clin Oncol</i>, 2011, 29(2):208-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/21115869/pubmed\" target=\"_blank\" id=\"21115869\">21115869</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bagatell R, Wagner LM, Cohn SL, et al, &ldquo;Irinotecan Plus Temozolomide in Children With Recurrent or Refractory Neuroblastoma: A Phase II Children&rsquo;s Oncology Group Study,&rdquo; <i>J Clin Oncol</i>, 2009, 27(15S) (abstract). </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Casey DA, Wexler LH, Merchant MS, et al, &quot;Irinotecan and Temozolomide for Ewing Sarcoma: The Memorial Sloan-Kettering Experience,&quot; <i>Pediatr Blood Cancer</i>, 2009, 53(6):1029-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/19637327/pubmed\" target=\"_blank\" id=\"19637327\">19637327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC), &quot;Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,&quot; <i>MMWR Morb Mortal Wkly Rep</i>, 1984, 33(14):198-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Sio L, Milano GM, Castellano A, et al, &quot;Temozolomide in Resistant or Relapsed Pediatric Solid Tumors,&quot; <i>Pediatr Blood Cancer</i>, 2006, 47(1):30-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/16047361/pubmed\" target=\"_blank\" id=\"16047361\">16047361</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Esteller M, Garcia-Foncillas J, Andion E, et al, &quot;Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents,&quot; <i>N Engl J Med</i>, 2000, 343(19):1350-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/11070098/pubmed\" target=\"_blank\" id=\"11070098\">11070098</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegi ME, Diserens AC, Gorlia T, et al, &quot;MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma,&quot; <i>N Engl J Med</i>, 2005, 352(10):997-1003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/15758010/pubmed\" target=\"_blank\" id=\"15758010\">15758010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegi ME, Liu L, Herman JG, et al, &quot;Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity,&quot; <i>J Clin Oncol</i>, 2008, 26(25):4189-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/18757334/pubmed\" target=\"_blank\" id=\"18757334\">18757334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horton TM, Thompson PA, Berg SL, et al, &quot;Phase I Pharmacokinetic and Pharmacodynamic Study of Temozolomide in Pediatric Patients With Refractory or Recurrent Leukemia: A Children's Oncology Group Study,&quot; <i>J Clin Oncol</i>, 2007, 25(31):4922-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/17971589/pubmed\" target=\"_blank\" id=\"17971589\">17971589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loh KC, Willert J, Meltzer H, et al, &ldquo;Temozolomide and Radiation for Aggressive Pediatric Central Nervous System Malignancies,&rdquo; <i>J Pediatr Hematol Oncol</i>, 2005, 27(5):254-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/15891559/pubmed\" target=\"_blank\" id=\"15891559\">15891559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marchesi F, Turriziani M, Tortorelli G, et al, &quot;Triazene Compounds: Mechanism of Action and Related DNA Repair Systems,&quot; <i>Pharmacol Res</i>, 2007, 56(4):275-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/17897837/pubmed\" target=\"_blank\" id=\"17897837\">17897837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Central Nervous System Cancers,&rdquo; Version 2.2011. Available at http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Non-Hodgkin&rsquo;s Lymphomas,&rdquo; Version 3.2011. Available at http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicholson HS, Kretschmar CS, Krailo M, et al, &quot;Phase 2 Study of Temozolomide in Children and Adolescents With Recurrent Central Nervous System Tumors: A Report From the Children's Oncology Group,&quot; <i>Cancer</i>, 2007, 110(7):1542-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/17705175/pubmed\" target=\"_blank\" id=\"17705175\">17705175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicholson HS, Krailo M, Ames MM, et al, &ldquo;Phase I Study of Temozolomide in Children and Adolescents With Recurrent Solid Tumors: A Report From the Children's Cancer Group,&rdquo; <i>J Clin Oncol</i>, 1998, 16(9):3037-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/9738573/pubmed\" target=\"_blank\" id=\"9738573\">9738573</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Herrstedt J, Aapro M, et al, &quot;Guideline Update for MASCC and ESMO in the Prevention of Chemotherapy- and Radiotherapy-Induced Nausea and Vomiting: Results of the Perugia Consensus Conference,&quot; <i>Ann Oncol</i>, 2010, 21(Suppl 5):v232-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/20555089/pubmed\" target=\"_blank\" id=\"20555089\">20555089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sarganas G, Orzechowski HD, Klimpel A, et al. Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. <i>Neuro Oncol</i>. 2012;14(5):541-546. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/22394496/pubmed\" target=\"_blank\" id=\"22394496\">22394496</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stupp R, Hegi ME, Mason WP, et al, &quot;Effects of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial,&quot; <i>Lancet Oncol</i>, 2009, 10(5):459-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/19269895/pubmed\" target=\"_blank\" id=\"19269895\">19269895</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Villano JL, Seery TE, and Bressler LR, &quot;Temozolomide in Malignant Gliomas: Current Use and Future Targets,&quot; <i>Cancer Chemother Pharmacol</i>, 2009, 64(4):647-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/temozolomide-pediatric-drug-information/abstract-text/19543728/pubmed\" target=\"_blank\" id=\"19543728\">19543728</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12823 Version 155.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F225270\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F225271\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1050179\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1050171\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F225246\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F225232\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1050182\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132830\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F225265\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1050181\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3402099\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F225305\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F225252\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F225236\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300110\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6223210\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F225266\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F225242\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F225255\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1050178\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F225235\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F225251\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1050186\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F4152326\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F225254\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F225257\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12823|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=temozolomide-drug-information\" class=\"drug drug_general\">Temozolomide: Drug information</a></li><li><a href=\"topic.htm?path=temozolomide-patient-drug-information\" class=\"drug drug_patient\">Temozolomide: Patient drug information</a></li></ul></div></div>","javascript":null}